| Theme | Therapeutic strategy for ulcerative colitis ; from standard to up-to-date | |
|---|---|---|
| Title | Medical therapy for ulcerative colitis during pregnancy | |
| Publish Date | 2011/05 | |
| Author | Reiko Kunisaki | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Hisae Yamamoto | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Hiroto Kinoshita | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Reikei Matsuda | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Machiko Nakatogawa | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Shinsuke Suzuki | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Hideaki Kimura | Inflammatory Bowel Disease Center, Yokohama City University Medical Center |
| Author | Shin Maeda | Department of Gastroenterology, Yokohama City University Graduate School of Medicine |
| Author | Mizuho Yamaguchi | Perinatal Center for Maternity and Neonate, Yokohama City University Medical Center |
| Author | Mika Okuda | Perinatal Center for Maternity and Neonate, Yokohama City University Medical Center |
| Author | Tsuneo Takahashi | Perinatal Center for Maternity and Neonate, Yokohama City University Medical Center |
| [ Summary ] | Ulcerative colitis does not seem to affect congenital abnormalities when the disease is inactive. However, active disease is a risk factor for preterm delivery and low birth weight. It seems the greatest risk to the mother and the fetus during pregnancy is active disease, and not the pharmacological agent used to treat it. Medical therapy for ulcerative colitis should generally continue during pregnancy and breast feeding, since the benefits of disease control outweigh the risks associated with medication. | |